This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Antimicrobial stewardship (AMS) is an approach aimed at promoting sensible use of antimicrobials, in an effort to preserve their future effectiveness.1,2 In clinical practice, stewardship translates as coordinated action to improve the use of anti-infectives and measure its appropriateness.1
The overarching goal of AMS is 3-fold:3
The principles of AMS are based on Public Health England’s ‘Start Smart – Then Focus’ guide, first published in 2011 and last updated in 2015, with information on implementing a stewardship programme, prescribing guidelines, and quality assurance measures.4 However, the toolkit was developed for broad antimicrobial use, without guidance specific to antifungal stewardship.
The terms ‘antimicrobial’ and ‘antibacterial’ are often used interchangeably, particularly in the context of resistance and stewardship. However, it’s important to note that antimicrobial is an umbrella term that covers all anti-infective therapies, including antivirals, antifungals, antibiotics, and antiparasitics.1,5
|Setting||Primary and secondary care||Mainly secondary care|
|Typical drug use||Treatment or single-dose prophylaxis||Prolonged prophylaxis and treatment|
|Drug availability and cost||Many drugs, £-££s||Fewer drugs, ££-£££s|
|Resistance||Increasing multi-drug resistance||Mainly single-drug resistance|
• Many drug interactions and contraindications
• TDM required (for certain azoles)
|Funding stream||National tariff||No national tariff (exempt from payment by results)|
At Pfizer, we have a long-standing commitment to tackling antimicrobial resistance, collaborating with the NHS and other stakeholders. We support an extensive range of initiatives that go beyond the sale of our medicines, including public awareness and educational programmes, education of healthcare professionals, responsible commercial and manufacturing activities, and investment in surveillance programmes.
ABS, antibacterial stewardship; AFS, antifungal stewardship; AMS, antimicrobial stewardship; PHE, Public Health England; TDM, therapeutic drug monitoring.
Click here for CRESEMBA® (isavuconazole) prescribing information
Click here here for Zavicefta® (ceftazidime and avibactam) prescribing information
Click here for Zinforo® (ceftaroline fosamil) prescribing information
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021